Revolutionizing Cancer Thereapy with 3-Dimentional (3D) “Synthetic Peptide” Drugs
Pepto*ID is engineering a new class of 3D precision peptide therapeutics that are already built in with stable drug-like characteristics to develop universally applicable targeted cancer care that overcomes drug-resistance.
Who We Are
Pepto*ID is a biotech innovator focused on designing and developing 3D synthetic peptide drugs that overcome the limitations of traditional peptide therapies and mutation specific, resistance developing traditional drugs.
By leveraging next-generation chemistry and biology, we engineer biologically stable 3D molecules with high selectivity, improved cell permeability, and enhanced therapeutic potential using novel mechanisms of action overcoming drug-resistance.
Our Platform Technology
Synthetic 3D Peptide Design Engine
Innovative design and synthetic tools for unique 3D-Synthetic Peptide design and optimization.
HTS Drug-Lead Identification
The unique On-Bead Two-Color (OBTC) High-Throughput Screening (HTS) technology that can quickly identify the most selective “hit” compounds for your favorite drug target over the rest of the cellular biomarkers – minimizing future failures due to off target effects.
Overcoming Drug Resistance
Mutation agnostic mechanisms of actions to avoid developing drug resistance.
Stability & Bioavailability
Already optimized “hit” structures directly identified with enhanced resistance to degradation and improved pharmacokinetics/pharmacodynamic (PK/PD) properties.
Scalable Synthesis
Robust manufacturing approaches enabling scalable production of clinical-grade Synthetic Peptide drug candidates.
OUR PIPELINE
PID-01
Mutation agnostic lead candidate directly targeting KRAS as a true “Pan-KRAS inhibitor” for advanced solid tumors (e.g. NSCLC, PDAC etc.); demonstrating potent anticancer activity in preclinical models.
PID-02
Next-generation therapeutic optimized for cell surface plectin for metastatic tumors with
the potential for combination therapy.
PID-03
Unique therapeutic targeting cell surface lipid-phosphatidylserine (PS) as a solution for
protein heterogeneity and therefore universally targeted cancer treatment development.
Discovery & Research Programs
Ongoing discovery programs focusing on novel cancer targets and resistant phenotypes.
Future Innovation
Expansion into universally applicable immuno-oncology targeted platforms leveraging
OUR TEAM
TANU CHATTERJI, PhD
Director, Startup Development and UH Technology Bridge Incubator
ALOE BLACC
Grammy-nominated, multi-platinum, singer/songwriter, known for major hits such as “I Need A Dollar”, “The Man”, and “Wake Me Up”, pledged early in his career to use his music for positive social transformation.
GOMIKA UDUGAMASOORIYA, PhD
Professor Udugamasooriya, affiliated with the University of Houston and the MD
Anderson Cancer Center, holds a number of patents and is a Senior Member of the
National Academy of Inventors (NAI) in United States